• News
  • SAN DIEGO
  • BioTech

Isis begins study for cardiovascular disease treatment

Carlsbad-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has initiated a Phase 1 clinical study for an anti-sense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
29.93
  1.28  
+ 4.47%
1,438,451,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
07/02/2014 Geary, Richard S 164 Sell $5,896
07/01/2014 O, Neil Patrick R 1,500 Sell $53,000
07/01/2014 O, Neil Patrick R 1,500 Exchange $15,435
07/01/2014 Crooke, Stanley T 17,500 Sell $622,559
07/01/2014 Crooke, Stanley T 17,500 Exchange $247,465

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!